{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:58:39Z","timestamp":1790272719342,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T00:00:00Z","timestamp":1471392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fixed combination calcipotriol 50 \u03bcg\/g (Cal) plus betamethasone 0.5 mg\/g (BD) foam has been developed as a new treatment option for patients with psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The randomized, parallel\u2010group, investigator\u2010blinded Phase III, 12\u2010week PSO\u2010ABLE study compared the efficacy and safety of Cal\/BD foam with Cal\/BD gel. Patients aged \u226518 years with mild\u2010to\u2010severe psoriasis were randomized 4:4:1:1 to once\u2010daily Cal\/BD foam, Cal\/BD gel, foam vehicle or gel vehicle (NCT02132936). The primary efficacy endpoint was the proportion of patients who were clear\/almost clear with a \u2265 2 grade improvement according to the physician's global assessment of disease severity (i.e. treatment success) at week 4 for Cal\/BD foam vs. week 8 for Cal\/BD gel. Secondary efficacy endpoints included: proportion of patients achieving at least a 75% reduction in modified psoriasis area and severity index (mPASI75), and time to treatment success (TTTS). Safety was monitored throughout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 463 patients were randomized: Cal\/BD foam (<jats:italic>n<\/jats:italic> = 185), Cal\/BD gel (<jats:italic>n<\/jats:italic> = 188), foam vehicle (<jats:italic>n<\/jats:italic> = 47), gel vehicle (<jats:italic>n<\/jats:italic> = 43); overall completion rate was 90%. Cal\/BD foam achieved higher treatment success rates (38% vs. 22%; <jats:italic>P<\/jats:italic> &lt; 0.001) and mPASI75 (52% vs. 35%; <jats:italic>P<\/jats:italic> &lt; 0.001) by week 4 than Cal\/BD gel by week 8. Median TTTS with Cal\/BD foam was 6 weeks; this could not be determined for Cal\/BD gel as 50% treatment success was not achieved (<jats:italic>P<\/jats:italic> &lt; 0.001). Adverse drug reactions were reported in 14 (7.6%) Cal\/BD aerosol foam patients and 7 (3.7%) Cal\/BD gel patients; all were single events except for itch with Cal\/BD aerosol foam (<jats:italic>n<\/jats:italic> = 5; 2.7%) and worsening psoriasis with Cal\/BD gel (<jats:italic>n<\/jats:italic> = 3; 1.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cal\/BD aerosol foam showed significantly greater efficacy after 4 weeks, than 8 weeks of treatment with Cal\/BD gel, with similar tolerability.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13859","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T10:56:39Z","timestamp":1471431399000},"page":"119-126","source":"Crossref","is-referenced-by-count":97,"title":["Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO\u2010ABLE study"],"prefix":"10.1111","volume":"31","author":[{"given":"C.","family":"Paul","sequence":"first","affiliation":[{"name":"Paul Sabatier University and Larrey Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cambazard","sequence":"additional","affiliation":[{"name":"Jean Monnet University Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Kalb","sequence":"additional","affiliation":[{"name":"State University of New York Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lowson","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bang","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre Salford Royal Hospital University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.014"},{"key":"e_1_2_6_5_1","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Krueger G","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_6_1","first-page":"167","article-title":"A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ\u20105D\u2010derived utility values","volume":"6","author":"M\u00f8ller AH","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030791"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1214-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2012.12.005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_2_6_13_1","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman WJ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6712"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04518.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04524.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096069"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07236.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13230"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000155642"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.492778"},{"key":"e_1_2_6_22_1","first-page":"S33","article-title":"Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle","volume":"134","author":"Hollesen Basse L","year":"2014","journal-title":"J Invest Dermatol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0269-7"},{"key":"e_1_2_6_24_1","first-page":"1468","article-title":"Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris \u2010 a randomized Phase III study (PSO\u2010FAST)","volume":"14","author":"Leonardi C","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_25_1","first-page":"34","article-title":"Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double\u2010blind, multicenter, three\u2010arm, Phase II study","volume":"9","author":"Lebwohl M","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1083935"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1446-x"},{"key":"e_1_2_6_28_1","first-page":"92","article-title":"Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double\u2010blind, vehicle\u2010controlled trial","volume":"12","author":"Menter A","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04967.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948194"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12445"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13859","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:31:09Z","timestamp":1694874669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/jdv.13859"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13859","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,17]]}}}